Sugi Predict

Sugi Predict / Compounds / SCHEMBL65018

SCHEMBL65018

SCHEMBL65018

COC(=O)c1ccc(C2CCNCC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ GAA P10253 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ CASP1 P29466 2/20 0.50
▸ CASP7 P55210 2/20 0.50
▸ ATM Q13315 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ HTT P42858 1/20 0.50
▸ GLA P06280 1/20 0.50
▸ TSHR P16473 1/20 0.49
▸ POLB P06746 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ TLR9 Q9NR96 1/20 0.47
▸ TLR8 Q9NR97 1/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ SLC18A3 Q16572 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL62143 0.98 HTT (0.49) KDM4EALDH1A1GAAHPGDCASP1
SCHEMBL231201 0.90 JAK3 (0.54) —
Hydrochloric Acid SCHEMBL9409494 0.89 JAK3 (0.52) —
Tert-Butyl Formate SCHEMBL28014694 0.88 HTT (0.41) KDM4EALDH1A1GAAHPGDCASP1
SCHEMBL13267179 0.88 ALDH1A1 (0.55) KDM4EALDH1A1GAAHPGDCASP1
SCHEMBL12488363 0.84 HDAC1 (0.56) KDM4EALDH1A1GAAHPGDCASP1
SCHEMBL16684739 0.84 HDAC8 (0.61) KDM4EALDH1A1GAAHPGDCASP1
SCHEMBL31704615 0.83 TLR9 (0.44) KDM4EALDH1A1GAAHSD17B10POLB
SCHEMBL31704607 0.83 TLR9 (0.44) KDM4EALDH1A1GAAHSD17B10POLB
SCHEMBL15239841 0.83 KDM4E (0.53) KDM4EALDH1A1GAAHPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2026-01-22 — — US claimed
EP-4561994-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS Genecode (EE) 2025-06-04 — — EP claimed
WO-2024023284-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2024-02-01 — — WO claimed
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2026-01-22 — — US disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 — — US disclosed
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2026-01-01 — — US disclosed
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 — — US disclosed
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 — — US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
WO-2001058886-A1 DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS NOVARTIS AG (CH) 2001-08-16 — — WO disclosed
US-6268369-B1 ALPHA SUB 1 INHIBITORS SYNAPTIC PHARMACEUTICAL CORPORATION 2001-07-31 — — US disclosed
EP-1021185-A1 DIDHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2000-07-26 — — EP disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 — — WO disclosed
WO-1998051311-A2 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1998-11-19 — — WO disclosed
EP-0790826-A4 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMA CORP (US) 1998-11-11 — — EP disclosed
WO-1997042956-A1 DIDHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-11-20 — — WO disclosed
EP-0790826-A1 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-08-27 — — EP disclosed
WO-1996014846-A1 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1996-05-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 KDM4E 167/4885ALDH1A1 959/4885GAA 159/4885
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS CNR1, CDR2, SMN1; SMN2 KDM4E 4619/4885ALDH1A1 1383/4885GAA 2022/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B KDM4E 384/4885ALDH1A1 2050/4885GAA 1459/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 KDM4E 1128/4885ALDH1A1 545/4885GAA 1379/4885
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, NCOR1, NCOR2 KDM4E 1055/4885ALDH1A1 3636/4885GAA 3925/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B KDM4E 141/4885ALDH1A1 1225/4885GAA 209/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 KDM4E 739/4885ALDH1A1 1790/4885GAA 860/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 KDM4E 167/4885ALDH1A1 959/4885GAA 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.